Mainz Biomed Advances Cancer Screening with Perfect Sensitivity in Pancreatic Study

Berkeley, Monday, 5 January 2026.
Recent study data reveals Mainz Biomed’s pancreatic cancer test achieved 100% sensitivity, driving a stock surge as the company advances its US FDA colorectal screening trials.